Achieve Life Sciences (ACHV) Cash from Financing Activities (2010 - 2026)
Achieve Life Sciences' (ACHV) quarterly Cash from Financing Activities came in at $21000.0 in Q1 2026, down 99.66% on a QoQ basis from $6.3 million in Q4 2025.
Achieve Life Sciences (ACHV) Cash from Financing Activities (2010 - 2026) Analysis & Trends
Achieve Life Sciences (ACHV) has 17 years of Cash from Financing Activities data on file, last reported at $21000.0 in Q1 2026.
- Quarterly Cash from Financing Activities changed N/A year-over-year to $21000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $11.0 million (changed N/A YoY) and the FY2025 annual result came in at $51.5 million, up 6.18% from the prior year.
- Cash from Financing Activities fell to $21000.0 in Q1 2026, from $6.3 million in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $56.1 million in Q1 2024 to a low of -$8.1 million in Q3 2024.
- A 5-year average of $7.2 million and a median of $682000.0 in 2024 frame the typical range for Cash from Financing Activities.
- The widest YoY moves for Cash from Financing Activities: up 119282.98% in 2024, down 101.0% in 2024.
- Tracing ACHV's Cash from Financing Activities over 5 years: stood at $17.7 million in 2022, then decreased by 14.01% to $15.2 million in 2023, then plunged by 95.52% to $682000.0 in 2024, then surged by 818.33% to $6.3 million in 2025, then sank by 99.66% to $21000.0 in 2026.
- The last three Cash from Financing Activities figures came in at $21000.0 (Q1 2026), $6.3 million (Q4 2025), and $4.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.42 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -6.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -207,909.22 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -273.15 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 36.24 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 27.18 Mn |
| 10 | Achieve Life Sciences | 330.88 Mn | 330.88 Mn | - | 168.46 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 168.46 Mn |
| Jun 30, 2026 | 168.46 Mn |
| Mar 31, 2026 | 21,000.00 |
| Mar 31, 2026 | 21,000.00 |
| Dec 31, 2025 | 6.26 Mn |
| Dec 31, 2025 | 6.26 Mn |
| Sep 30, 2025 | 4.04 Mn |
| Sep 30, 2025 | 4.04 Mn |
| Dec 31, 2024 | 682,000.00 |
| Dec 31, 2024 | 682,000.00 |
| Sep 30, 2024 | -8.11 Mn |
| Sep 30, 2024 | -8.11 Mn |
| Jun 30, 2024 | -153,000.00 |
| Jun 30, 2024 | -153,000.00 |
| Mar 31, 2024 | 56.11 Mn |
| Mar 31, 2024 | 56.11 Mn |
| Jun 30, 2023 | 15.23 Mn |
| Jun 30, 2023 | 15.23 Mn |
| Mar 31, 2023 | 47,000.00 |
| Mar 31, 2023 | 47,000.00 |